Synthesis and muscarinic activities of 3-(pyrazolyl)-1,2,5,6-tetrahydropyridine derivatives.
A series of 3-(pyrazolyl)-1,2,5,6-tetrahydropyridine derivatives (B) was synthesized and tested for muscarinic activity in receptor binding assays using [3H]-oxotremorine-M (3H-OXO-M) and [3H]-pirenzepine (3H-PZ) as ligands. Potential muscarinic agonistic or antagonistic properties of the compounds were determined using binding studies measuring their potencies to inhibit the binding of 3H-OXO-M and 3H-PZ. Preferential inhibition of 3H-OXO-M binding was used as an indicator for potential muscarinic agonistic properties; this potential was confirmed in functional studies on isolated organs. All compounds with agonistic properties showed 3H-PZ/3H-OXO-M potency ratios in excess of 20. In contrast, for antagonists this ratio was found to be close to unity. Mono-halogenation resulted in compounds (4b and 4d) with M3 agonistic properties as shown by their atropine sensitive stimulant properties in the guinea pig ileum, but with very little or no M1 activity. Some minor in vivo effects were observed for both these compounds, with the iodinated compound 4d inducing salivation. Compound 4d also showed some positive mnemonic properties in rats where spatial short-term memory had been compromised by temporary cholinergic depletion. These data indicate that some M3 agonism may be desired in therapeutic agents aimed at the treatment of the cognitive deficits of Alzheimer's disease patients.
Plate
R
R
Department of Medicinal Chemistry, Scientific Development Group N.V. Organon, The Netherlands.
Plaum
M J
MJ
de Boer
T
T
Andrews
J S
JS
Rae
D R
DR
Gibson
S
S
D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine / Q000737:chemistry* / Q000378:metabolism; D000544:Alzheimer Disease / Q000188:drug therapy; D000704:Analysis of Variance; D000818:Animals; D001667:Binding, Competitive; D004195:Disease Models, Animal; D015259:Dopamine Agents / Q000737:chemistry* / Q000378:metabolism; D007553:Isotope Labeling; D008297:Male; D008568:Memory / Q000187:drug effects; D008745:Methylation; D051379:Mice; D015877:Miosis / Q000139:chemically induced; D018721:Muscarinic Agonists / Q000138:chemical synthesis* / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use; D018727:Muscarinic Antagonists / Q000138:chemical synthesis* / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use; D015878:Mydriasis / Q000139:chemically induced; D010095:Oxotremorine / Q000378:metabolism; D010890:Pirenzepine / Q000378:metabolism; D011817:Rabbits; D011869:Radioligand Assay; D051381:Rats; D017208:Rats, Wistar; D012472:Salivation / Q000187:drug effects; D013329:Structure-Activity Relationship; D014649:Vas Deferens / Q000187:drug effects / Q000378:metabolism
D015259:Dopamine Agents; D018721:Muscarinic Agonists; D018727:Muscarinic Antagonists; D010890:Pirenzepine; D010095:Oxotremorine; D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine